Researchers report promising results from an off-the-shelf cancer vaccine, ELI-002 2P, in preventing the recurrence of pancreatic and colorectal cancers. The vaccine, containing peptides targeting Kras gene mutations, elicited a strong immune response in 17 out of 25 patients, leading to longer survival and delayed cancer return. While the study is small and needs further investigation, experts suggest its potential for wider use and combination with other immunotherapies due to its cost-effectiveness and reduced toxicity compared to personalized mRNA vaccines. Larger trials are needed to confirm these preliminary findings.

Prepared by Olivia Bennett and reviewed by editorial team.